{"log_id": 5893051207595223382, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 4.9e-05, "average": 0.992421, "min": 0.982266}, "location": {"width": 57, "top": 156, "height": 27, "left": 184}, "words": "[禁忌]"}, {"probability": {"variance": 0, "average": 0.999516, "min": 0.999516}, "location": {"width": 37, "top": 143, "height": 35, "left": 1168}, "words": "监"}, {"probability": {"variance": 1e-06, "average": 0.999171, "min": 0.996265}, "location": {"width": 412, "top": 199, "height": 33, "left": 223}, "words": "对本品中活性成份或其他任何成份过敏者"}, {"probability": {"variance": 8e-06, "average": 0.998214, "min": 0.988596}, "location": {"width": 412, "top": 249, "height": 34, "left": 211}, "words": "脓毒血症患者或存在脓毒血症风险的患者"}, {"probability": {"variance": 3e-06, "average": 0.998984, "min": 0.992036}, "location": {"width": 705, "top": 294, "height": 39, "left": 221}, "words": "对包括慢性或局部感染在内的严重活动性感染的患者不能使用本品治疗"}, {"probability": {"variance": 1.6e-05, "average": 0.997608, "min": 0.989726}, "location": {"width": 99, "top": 403, "height": 28, "left": 181}, "words": "[注意事项"}, {"probability": {"variance": 5e-06, "average": 0.99841, "min": 0.994627}, "location": {"width": 93, "top": 453, "height": 26, "left": 177}, "words": "特别警告"}, {"probability": {"variance": 5e-06, "average": 0.99863, "min": 0.98797}, "location": {"width": 815, "top": 490, "height": 40, "left": 220}, "words": "曾有使用依那西普发生严重感染(包括脓毒血症和结核病)的报告,一些是致命感"}, {"probability": {"variance": 9e-06, "average": 0.998299, "min": 0.988074}, "location": {"width": 861, "top": 540, "height": 41, "left": 175}, "words": "染。这些感染是由于细菌、分枝杆菌、真菌和病毒引起的。也曾有机会致病菌感染的报"}, {"probability": {"variance": 1.7e-05, "average": 0.998086, "min": 0.979675}, "location": {"width": 860, "top": 590, "height": 41, "left": 175}, "words": "告。需要对在依那西普治疗过程中出现新发感染的患者进行严密监测。如果患者出现严"}, {"probability": {"variance": 4.1e-05, "average": 0.99773, "min": 0.961053}, "location": {"width": 861, "top": 638, "height": 42, "left": 175}, "words": "重感染必须停止使用依那西普。复发性或慢性感染的患者或存在可能导致患者易受感染"}, {"probability": {"variance": 1e-06, "average": 0.999085, "min": 0.995648}, "location": {"width": 549, "top": 691, "height": 37, "left": 176}, "words": "的潜在条件,当考虑使用依那西普治疗时,应谨慎使用"}, {"probability": {"variance": 0.002935, "average": 0.989249, "min": 0.683274}, "location": {"width": 818, "top": 736, "height": 39, "left": 219}, "words": "依那西普和阿那白滞素( Anakinra)联合治疗与严重感染和中性粒细胞减少症的风"}, {"probability": {"variance": 5e-06, "average": 0.99847, "min": 0.990764}, "location": {"width": 864, "top": 784, "height": 42, "left": 173}, "words": "险增加有关。由于并未证实该联合治疗可以增加临床疗效,因此不推荐依那西普和阿那"}, {"probability": {"variance": 1e-06, "average": 0.998596, "min": 0.997035}, "location": {"width": 162, "top": 843, "height": 33, "left": 174}, "words": "白滞素联合使用"}, {"probability": {"variance": 0.006531, "average": 0.981582, "min": 0.512113}, "location": {"width": 795, "top": 883, "height": 40, "left": 244}, "words": "项在180例标准治疗(包括环磷酰胺和大剂量激素)上加用依那西普的 Wegener’s"}, {"probability": {"variance": 3e-06, "average": 0.998674, "min": 0.993793}, "location": {"width": 864, "top": 931, "height": 42, "left": 173}, "words": "肉芽肿患者的安慰剂对照研究中,与单用标准治疗相比,加用依那西普组患者的临床症"}, {"probability": {"variance": 0.000279, "average": 0.995624, "min": 0.896847}, "location": {"width": 856, "top": 980, "height": 41, "left": 171}, "words": "状未改善更佳。依那西普治疗组患者与安慰剂组相比,发生各型非上皮恶性实体瘤更多"}, {"probability": {"variance": 0.012259, "average": 0.972458, "min": 0.502828}, "location": {"width": 480, "top": 1034, "height": 39, "left": 173}, "words": "不推荐 Wegener's肉芽肿患者使用依那西普治疗"}, {"probability": {"variance": 3e-06, "average": 0.998808, "min": 0.991792}, "location": {"width": 824, "top": 1077, "height": 41, "left": 216}, "words": "在一项48例使用依那西普或安慰剂治疗的中度到重度酒精性肝炎住院患者中进行"}, {"probability": {"variance": 5e-06, "average": 0.999034, "min": 0.986855}, "location": {"width": 869, "top": 1124, "height": 43, "left": 172}, "words": "的试验表明,依那西普治疗无效,且治疗6个月后,依那西普治疗组患者的死亡率明显"}, {"probability": {"variance": 0.000113, "average": 0.996982, "min": 0.93355}, "location": {"width": 871, "top": 1173, "height": 42, "left": 171}, "words": "较高。不推荐酒精性肝炎患者使用依那西普治疗。患有中度到重度酒精性肝炎的患者使"}, {"probability": {"variance": 1e-06, "average": 0.998918, "min": 0.995705}, "location": {"width": 373, "top": 1229, "height": 35, "left": 171}, "words": "用依那西普治疗时,医生应谨慎使用"}, {"probability": {"variance": 1.3e-05, "average": 0.997957, "min": 0.980226}, "location": {"width": 826, "top": 1270, "height": 42, "left": 216}, "words": "溶剂的预填充注射器橡皮塞中含有橡胶(干燥天然橡胶)。在接触或使用依那西普"}, {"probability": {"variance": 1.8e-05, "average": 0.997833, "min": 0.977388}, "location": {"width": 872, "top": 1319, "height": 43, "left": 168}, "words": "之前,患者或护理人员应联系医生询问如何处置已知或可能对橡胶产生的超敏反应(变"}, {"probability": {"variance": 4e-06, "average": 0.998565, "min": 0.994954}, "location": {"width": 87, "top": 1382, "height": 28, "left": 171}, "words": "态反应)"}, {"probability": {"variance": 2.1e-05, "average": 0.997284, "min": 0.987319}, "location": {"width": 138, "top": 1480, "height": 26, "left": 174}, "words": "一般注意事项"}, {"probability": {"variance": 0, "average": 0.999981, "min": 0.999979}, "location": {"width": 50, "top": 1531, "height": 25, "left": 171}, "words": "感染"}, {"probability": {"variance": 0.000243, "average": 0.995745, "min": 0.902322}, "location": {"width": 825, "top": 1565, "height": 40, "left": 218}, "words": "由于依那西普的平均消除半衰期约为70小时(范围:7-300小时),因此在使用依"}, {"probability": {"variance": 1e-06, "average": 0.998588, "min": 0.996704}, "location": {"width": 142, "top": 1625, "height": 26, "left": 170}, "words": "版本号:20090"}, {"probability": {"variance": 1.7e-05, "average": 0.997302, "min": 0.987519}, "location": {"width": 165, "top": 1613, "height": 29, "left": 792}, "words": "第9页共31页"}], "language": 3}